ADXS - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Advaxis Business and Clinical Development Update Call. All lines have been placed on mute. At this time all participants are in listen-only mode.

Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today, November 2, 2018. to call like Miller. to now would turn over the Miriam I go Please ahead.

Miriam Miller

is LHA, today's Miller Agency morning. Miriam Good This with Thank for for you the participating in call. Advaxis. Relations Investor

are Ken Chief and Henderson, Dr. Dr. Joining me Petit, Officer; from Berlin, and Scientific Officer; Financial Medical Chief Chief Gutierrez, Chief President Andres Robert Molly Executive Officer; Advaxis Officer.

company's this press release to the Before a highlighting issued the clinical morning, market strategy. Advaxis opened development changes

would New you to this list, with news XXX-XXX-XXXX release to you company's be and If not the if added have received please or call York speak like e-mail distribution Curran. LHA Carolyn in at

without the of this call from conference call. by turn I’d Ken the day contains to to events other to of risk or and and the said, Berlin. to may with statements time-sensitive limitation, revise of its company's events XX, X-K. over XX-K that management we those call statements factors Except the of described SEC like to you results reflect on October will Form I XX-Q I'd that Form this as like identify comments risks operations November forward-looking obligation filed December conference These information the that forward-looking encourage the during differ to or periodic regarding future accurate actual required and related remind after ended year content uncertainties circumstances Before and Advaxis. call to filings other the update X, Advaxis law, that specific to the results no for the business undertakes this materially filings by fiscal the made XXXX. Ken? SEC review contain begin, including With involve in statements company's factors XX, or any as cause including, date reports only XXXX of and you that live operations. XXXX the filed broadcast, is Furthermore,

Ken Berlin

thank Thanks, Miriam. and Good morning, you joining us. for

our advancing our investor to we've and stands since During on work I the call, direction hard of period update an at this been five-month where share last today. clinical pipeline plan programs, the

My though, Advaxis. initial you the share for time we I Before conclusion assessment It tremendous what together platform's drug presented the with but I've at collaborators have of of candidates potential opportunities lives I and My the time assets my opinion impact when six that key not as in company. joined Advaxis, receive excited joined the have all discussions company's a company's made that these was and will become. resulted by months in it our bullish ago been at spent more I KOL with also shareholders months people say people, honestly joined presented about can period me and inputs while about than that, myself I us, a new have of data field. prospects still fighting the and company. had why relating science, do some ahead work leaders intrigued data information continually on I we only being value since create in busy I to we six I and that its very has immersing to was been could cancer. our the the multiple the me immune-oncology opportunity has Advaxis

locally axal for secure this a readout cervical recall would Advaxis if estimated filolisbac, the which partner could advanced due wind until we Phase total XXXX, the cost You'll AIMXCERV not was to not least readout at in million. to past that expected that was trial, decision down cancer. Advaxis evaluating That and be axalimogene part that axal, that $XX would data June, the fact to X occur in to a high-risk stated get is

have funding. new Advaxis in of and we broad Advaxis require In addition, product a portfolio candidates our that programs, HOT, neoantigen-directed NEO

several a engaged that with number for in past in conversations optimistic the the field we've experts months, the of increasingly about AIMXCERV. extensive made Over prospects us

have in Lm-based investment the in that therapies. the AIMXCERV path product believe forward We We to candidates, of best determined to for continued other our demonstrate therapy certain cancer, and cervical addition provides us is well and of of cancers product drug future. path interesting pipeline an the with combination constructs, cancer for stages diversified development, us across modalities, positioning this types, stages effectiveness

move with you how plan with we forward discuss will AIMXCERV. I to Now

investment that have, provide revising changes the XXXX. are believe changes, and would as the the other The currently potentially we well meaningful more certain include as place would shorten us. order earlier informative interim namely protocol a milestone, than futility required certain and study what if the and milestone to would analysis, this reach expected benefits beneficial. time in hopefully FDA, AIMXCERV to early other we amended as as important reduce We assessment an to approved process of by that be analysis to take earlier to in provide to an a be These provide interim

design. monitoring having couple FDA proposed data revisions or study, from proceed the as AIMXCERV stop a next XXXX. the to the the early trial will analysis as on Over committee anticipate recommendation to we the quarter FDA work finalize we accepts the of months, interim the fourth trial to based with If of revised our

interim work the are amend we analysis. We proceed to patients from and study as study to amend the the protocol continuing with permission secure to enroll revised FDA

for We power a to survival that cost statistical broad revised a continue outcomes. We estimate is to adequate AIMXCERV the point plan interest partners. million for the over maintain the interim continue to further will that which the to partnerships range and in drive sample the million. $XX sufficiently from explore analysis supports subjects, continuation will interim large potential of XXX be bring readout of believe parallel, about an approximately size of In would to $XX axal program we earlier that to

events continuing in cancer XXX has robust with experience. axal study We has To research as head treated to initiate AIMXCERV drug, it sharing be manageable with with early our to to neck XXXX. on axal, date, it axal for addition we trial a information able as safety and soon been have that has management In a patients relevant center over tolerated company demonstrated and look we available. more establish becomes trial about this and investigator-sponsored shown to profile. to using plan The the well guideline an forward major adverse based a in also

other programs. Now let's turn our to

presented our patients I/II study subjects PSA Advaxis in study collaboration overall metastatic, greater We a of of in early prolonged with drug cancer. with in nearly in subjects ASCO KEYTRUDA in the prostate treated or this combination this data XX% subjects are suggested earlier follow Phase survival in XX castration-resistant continuing in from PSA with arm year Intriguing XX% through study. to of of at all decline the combination baseline a Merck from

We XXXX. correlative overall the this survival expect update on an of with provide to for biomarker quarter in study, first data, along

position which fight that approach to are capacity category. and critical and few of are neoantigen-directed programs. case drives care off-the-shelf-based help response neoantigen will of Advaxis creating in the and Advaxis antigens, based us neoantigens among NEO, new Advaxis antigens. large about tumor that the leadership the are HOT, discuss patient's patient-specific products a constructs NEO, constructs by cancer in highest have that which in as or unique, cancer a targeted immune public neoantigens against a are on can express emergence vectors that our a T-cell express development unique Advaxis transform I our shared neoantigens platforms system our a tool mutations target the in both of approach today. believe personalized HOT. The achieve neoantigen aspects Both within approach enable the a We to it Lm-based capacity of which activates believe A on neoantigens, we which high potential of number the these case Now

broad intriguing Advaxis platforms Advaxis Another about their and both is aspect NEO applicability. HOT

directed all In types, nearly broad towards can to cancer a these creating impact tumor the fact, of significantly range of for potential patients. each be us platforms

trial being collaboration a in Advaxis announced, NEO clinical types cancer previously several we Amgen. As is for with evaluated in

patients and data trial half our providing from for our plans anticipate initial HOT first tolerability candidates. safety, now immune in We correlative patients and are Advaxis this drug the our in off-the-shelf of cover enrolling XXXX. I'll

lung with cancer. begin in XXX, Advaxis drug cell study We KEYTRUDA monotherapy as plan to Let's our candidate. both leading Advaxis non-small in combination with HOT and XXX

and to this have the this of end and Advaxis safety, in first subject of this anticipate readout of first data XXX in by study immune Phase half a expect enrolled XXXX. correlative the for first X/X the year, from cohort tolerability We

ensure in level, are programs. I've testing of clinical and We early these constructs funding development adequate will prostate aforementioned financial for today. clinical cancer the we additional Advaxis until outlined the ensure to cancer corporate the bladder plan in XXXX to support delay for our steps HOT order taking At

combination First, cancer we the treatment study cancer. HPV-associated refractory in durvalumab or our and in recurrent not with advanced will neck Phase patients axal head continue of for X/X of enrollment with and cervical

recurrent the We with women AIMXCERV indications will with than are that Note seeking advanced carcinoma treatment of study initiate what of or the for these our cervix. we persistent, the study. are also not different metastatic

months. look the at have several we over a Second, take hard continued to our costs past

that our our approximately As $XX net result earlier cost a measures, year. annual this This cash $XX anticipate million burn down we million. be now is of from over will control

space with Lm in immune induction platform. believe in We activity. portfolio that for patients in assembled of we've ability safety and what a have treatment cancer. candidates to in XXX changes product profile, outlined we months. are body experience, neoantigen-directed a natural the that control next to differentiate demonstrates the Lm more reiterate I've and infection multiple we believe least on I our positioned sufficient efforts, drug data have With I than fund our clinical with is, to our believe to uniquely mimic To development trials, our strongly our response also based coupled cash to of and expertise unique today, a manageable a candidates been from against strong of constructs want redirect and and June, potent others that Advaxis our at treated technology this succeed responses clinical our we program cost immune we back that date, segment said by the XX

alerts these we ahead from immune enhanced that and system, with and coupled and opportunity cells activates believe stages AIMXCERV, various partners, cancer-specific tumor, on the diverse both generating provides vectors such and at to in range of benefit immune the system. aggregate the approach, created the have multiple a opportunities microenvironment forward conjunction shield the of with for candidates, a portfolio programs, target drug and of the from development, moving This conjunction unique Ultimately, of types. nearer-term commercial our which look of assets portfolio our robust many multiple extremely a for range for the tumor earlier-stage potential to tumor pursuit presentation, people Our the in and readout reducing attack help in the from who an to broad our diversified that we response trains internally Tregs stand and programs. tumor which provide T-cell we with programs, mobilizing MDSCs pathways which in antigen as and to thereby and tumor-protective monetization success,

a this we take prior more months reiterate team some our about supports We team's commitment creation we immediately today been position challenging made to value. to Before of important the difficult I to for believe with shareholder I changes necessary I last the our and more six have the to here both meaningful am The and but moving that diversified goal. have was prospects portfolio success. questions, at rewarding, forward Advaxis. that joining optimistic as want company

With you and catalysts, firmly number outlined forward near-team and best the and overview, I it. the leading support to further We Lm I’ve is versatility about for programs data Advaxis of to ready believe continuing on to to share several first the including our demonstrate to a company. readouts the your questions. management into have Angela? path half Advaxis future of We programs during continue with XXXX. the are to of our Furthermore, and look the a platform our On build excited way and strength immuno-oncology thank Robert behalf half of board our we during today first we are of team progress you. I Molly, Andres, take as of monetize of that our directors, potential

Operator

AGP. Instructions] question [Operator Jim Our from Molloy first is with

Jim Molloy

ADXS-HOT/-XXX the had half just some Hey I question. look quick of guys, thanks question first on the non-small-cell my here, program, for interim a taking XXXX. lung

– last that think out still trial that – goes had I you first still the Is up on to Assuming all? XXXX. you’re wrap get that expectation half been track, pushed does would that well, or when at

Ken Berlin

Jim, don’t get your want just clarify Hi programs. for Thanks we asking, make good confused I right? to sure across question. want I So what the morning. you’re to dates

assembling So Advaxis patient soon soon. expect Advaxis within the test next we’re correlative from through first to HOT, will patient, having And cohort we cancer lung by the anticipate of this that We’ll which patients the study our patients from have data by or they year, safety, in program, is will and, immune candidate the the first of importantly, the we be of study. XXXX. as half of data year this HOT those certainly, the particularly data consist XXX, as he’ll of biomarker by we non-small-cell half first that first dose that our end first dosed Phase and assemble I/II thereafter. tolerability And drug come

this bit what we can we But that see about working upon In your KEYTRUDA flexible about number What operations of is of directions, very in take the could with have into in also a the that of things. well, and that, study patient in that talking talk a early depending on for hopefully of stages and team us done that Andres little his combination a Andres clarifies clinical terms different depends completion question. and population, study, designed too. are study,

Andres Gutierrez

dose escalation in the – cancer. goal dose has three as the in indication, combination monotherapy, A so B lung been part to is a Part expansion with non-small-cell three with is in have dose parts. designed a study escalation KEYTRUDA combination Part Part Yes, in different well, KEYTRUDA, is

parts XXXX. completed most So escalation in in will – be sometime The dose again, it depends. early likely

Ken Berlin

that answer question. your Jim, does

Jim Molloy

they’re very does. IND as of Then I it’s much. hard it to Yes, they sort and very growing you when Thank the are and the Phase I – – so know Everything file moved or the – that go, describe prostate that Yes, much. will XXXX file trials. year, another get the you these saying the trials of IND of pushed sort INDs, on other appreciate the you rest now will IND of – as HOT, sort to the still Will on XXXX? the still – those this gets out for you’re well? for out

Ken Berlin

question. Jim, So, really that’s good a

our stated, we commencement pushing as the clinical helps our candidate we our forward. which enable revised prostate really So and the of bladder are cancer for path off program, to studies from this clinical cancer drug candidate HOT drug fund

particularly it ahead something It’s the and for possible relates internally. that so. still IND prostate, file that’s sense it go make around reasons, very As various assessing submission we’re may we’ll still to IND; do to

it able hard to And file the when so to team to sense decide be to whether position I comes. it know file working the in is and be ultimately we’ll it, makes a time

Jim Molloy

question, hop queue. back last I’ll the in and Okay,

been were sort forward AIMXCERV of through you limited have out continue? the – way that you to go pushed expanding recently that walk key the let’s to what said, for data on was on saw HOT the you drivers it fair resources, trial? resources, the make that obviously, key On Is through that? drivers AIMXCERV augmented Can walk for with cervical, the although that what the can trials on

Ken Berlin

But with and Sure, Jim. I’ll to question. never answer really as try the white. black it’s everything,

You So portfolio believe, comments, past. confidential, are I at company have looked best factors, success earlier success and right? to drug past of best said many prepared of in for gives demonstrate cervical that axal effective press talked release these a especially and path optimistic in months, look to all chance to drug the it’s the about candidates we’ve had preclinical best that into today of that account rather or are candidates right? so determine as the the over constructs, those number II that I we optimistic some candidates analysis discussions, drug to items important forward number factors and to We’ve with studies of around we’ve is a forward data could is, have portfolio us the are, and AIMXCERV what in it’s details and trial get these about prepared – which the our into our statements, really product say become reason many had also we more the my when and company’s we’ve moving folks, the those. cancer, study forward. a described positive We a five your believe than constellation the So success the different within for now believe in different Lm-based positioning we portfolio, as you so multifactorial remember, as therefore at going how different Phase clinical so we that of inputs, this in have all also the we lot my make we portfolio, it of take which of

Jim Molloy

I that your which one and last first fiscal fourth Oh, to quarter XXXX actually too, question, opposed quarter reference bit? XXXX, the just off quarter, are calendar a bookkeeping. you as quarter – to did, little that’s guys obviously clarify – is XXXX, fourth When

Ken Berlin

Correct, right.

financial So ones data about our reporting, that’s calendar, all readouts but when are we we describing, those talk quarters. and the about like financials you’re on when talk financial calendar

Jim Molloy

much. very you Thank

Ken Berlin

Thanks for your Jim. questions. you, Thank

Operator

H.C. Wainwright. next question Your Swayampakula from is with

Swayampakula

I Ken. have questions. Thanks quick a for update. morning, the Good of couple

of part it, it FDA, it the on does AIMXCERV Just the impact FDA? so initially the designed changing then you’re – or have changes, with that making now FDA still was within program, on on any is

Andres Gutierrez

are analysis, FDA stringent proposed the is the pretty approve have able better turning again, be of to earlier establishing enough support we to is course – we a going the believe redesign. And a a interim that redesign boundary much, the to allows to just what’s of before kind we because So of up data our set point the to us futility more have study. that in

Swayampakula

just I’m continue to provide you. understand study? there termination to you what with And made just not trying then, durva anything Thank decide understand Is the what to led us that study that can [indiscernible]. with the the you of to

Ken Berlin

RK. Thanks,

trying So to we’re can. know as it I clear as we make

the think, look first said, a strategies while in once to smart this number or factors I to got the So we we’ve get which analysis, this while I look kept named to we that external you right? It’s of to a to had get partner I’ll certain had our talking give risk, to a at. going tried And company, partner, answer revised the we quote, are those eyes didn’t black open costs not in able it be every believe right? As to down interim especially question, a good this that that’s intended to it’s been to thing, on AIMXCERV white, analysis, the will of a to the or leaders. company, to encapsulate what And wind based before. we Churchill, explain, but down interim Winston a guy on we as to we internal bunch right? degree, find key opinion meaningful all with so, redesigned everything if at you’ve than results, more factors, a

portfolio other interesting forward. the the Phase these right is the asset. think X one us very we’ve forward for we a that’s all path with with that believe starting success, believe best And it’s considered, that And to what factors to plus we that, position portfolio, proceed this the company is So right? make

center The in – which IST, early in We have drug program prostate NEO. neck with asset year be lung head Phase and hopefully, a our new our have cancer. We’ll with asset and X/X as know. X with HOT a axal X you cancer, major in a Phase a candidate Phase Phase cancer will X/X research study, next an

importantly, we that’s portfolio, a substantially. reduced burn So we’ve and our intriguing think rate very

that rate $XX burn you down $XX-million portfolio, we when when against million pretty annual by against cash greater back, broad to a a the than going XX% look same So almost portfolio. we’ve had brought

adjusted I as monetization for way commercialization. us and and data inflection think our with as So And opportunities for for we readouts, shots on going forward. are all think think well there our as the positions multiple we cash and/or with goal as runway as relates points much have, possible success these it cash to it we burn

Swayampakula

not providing if sure you a run the what you Thanks this point, million that – question so before you this this? of $XX far should call. need I if How can expect have for segue, kind at Ken, back we go financials I go ask on market? can was rate this to The a because from to

Ken Berlin

finance you because can ask Molly’s them. So answer I here will – questions to

Molly. So I’ll to over turn it

Molly Henderson

sure, Hi, yes.

for So and look mentioned and anticipate sure we our past prepared in looking will we're cash current as make remarks, Certainly want we programs we XXXX next the for into as to positioned his on XXXX expanding appropriately. Ken least at us our anticipate that financially that beyond, take XX that we months. and

looking we've is be at believe of the and ourselves from in and runway, a which lot to We'll let's of will dilution, is, partners. equity readouts, which the the get relation done, we potential mindful let's at interest, currency opportunities. we're but key all our point data So where certainly both markets give solicit

we've So enough also path sure here. think runway the mindful, we be but to continue exists of that's to got what want again, forward, demonstrate to make our and we stock really price, we

Ken Berlin

is, nondilutive the effort, preferred. valuations are and strategy, certainly curious takes know can, very I the at that about is is. to time, underscore business fact Molly some to development what development business course shareholders Because And a lot mentioned, if of answer be it right? our the a particularly of second, just for our I if And takes of want at would just know mindful and and we I talk are it RK, we're of financing, part of can today, it

we want rest that a guarantee outcomes just very – on. the but development of can't we're assets. – things development the do a is want partnerships discussions help would assets, be have a of because we that those discussions, of have those I I number lot much business of doing, We people and going assured prominent to frankly, in to So feature accelerate

something a and we data it's of first And it working so are we the obviously, year takes readouts help bit coming at, will that, And in time. of the are half that, believe. next that

to just point, I underscore it does relate because of the to So back wanted sort financing and runway. cash

Swayampakula

talking with for Yes, the about coming Amgen And years, is of half relationship Ken, partnerships, of couple a the and the or up think, early – I XXXX. up, of running data in now. first part

with is So what it there associated now? should than anticipate you maturing that this? how milestones into – something we do And relationship is any bigger

Ken Berlin

try of both So I will questions. address to those

publicly the to disclosed relate and they items. other sales-based So progress, to than we milestones success regulatory haven't aggregate that $XXX and development million

we'd are I offer royalties do, been insights very partner, behalf to input. Amgen detail get other on milestones very but agreement. I obviously in them every are of what to to speak engaged out love the the the and those our they've are of part addition a on certainly terrific want say partner that more collect and $XXX of into achieve those, than that in million there, can't and So to don't one single helpful we

I these on for patients candidates, both we're as drug are seen in be Now, very of level course, see Amgen all relates data and look, program, to done, patient each to preclinical where NEO the in NEO pleased. the that it if that personalized data then our looks a folks of the on the have excited the anything we've we're think the drug the and first seen I like work candidates and we'll products, the high we've immunogenicity, experts think Lm Robert

Swayampakula

and Thank my you, thanks all questions. taking Ken for

Ken Berlin

Right, okay.

Operator

next from AFM is Martin with Saltzman Investments. Your Instructions] [Operator question

Martin Saltzman

I to call. could Hi, have brought I just me, taking valuation if answered wanted expand you thank how were today, several there the that you for already ask been because my more Ken, but specifically upon up guys feel wanted that. you ask, to about for company's things just about

Ken Berlin

I’m and the Martin, There to that try talk avoid short-sellers we are on stock, the of things not moment talk we're thanks we the going fundamentals. and of the to morning, Good valuation going that need but about are Elon doing. several to to these for the Musk question. about are -- or control. an so done I'm what things and we And do that believe can help needed to company, we've change the manipulation focused

asset a So was AIMXCERV, bringing portfolio, us one thing a a what for are surrounding plans that certainly was important. AIMXCERV we've was to our taken important I around bring some That of Phase right? clarity and uncertainty around do step are to on, believe for III that and clarity lot people focused big our overall which is

data to those relate to coming, our made cash some popular rate that TV very what to a just we've And is which HBO, paraphrase cash, we at show giving around our to burn, the where cash perhaps that's we three really catalysts the out where we've and runway burn very It's significant are. we've And get pretty really is quiet, to to catalysts when cash through so at drive at what right? we things: company coming. We will important -- million, data, to catalysts, now these are on a progress. about about and burn overused have and us data coming and to of clarity got down valuation. phrase for the think next. do, we we've data, we're that's it's from it's an been allows were thing, And that but and a obviously, been burning $XX where portfolio this Second one pretty period day, you Still, end data right? cash of Because a turn the $XX- are with rate work million a runway similar nevertheless, described significantly, some I'll brought morning, annual a right?

programs our in we've So got three first next as we've the year. data of half said, from of readouts

in a seeing Advaxis the the response from a Not First, KEYTRUDA, combination of subset very about interesting too in combination Advaxis PSA with with study patients we are our of XX% of in patients. PSA where study small; KEYTRUDA.

data Next, readout share half NEO we excited patients talked least, about program, first the next which having on in we're not year. of in to the first data And last from but first the it. of from coming data half of preceding have lot studies, Again, where program. had a a lung coming HOT next quiet clinical our the we've year, period we out from

if catalysts, successful which course, but catalysts will So, company. and and development are working the front, guaranteeing the help of we think we're things on important that, will those business we're data at, for we're be important certainly those not

those done So we have should question? that are your we're and think things help that answer going doing that forward. important Does the three

Martin Saltzman

but we today? come answers now figure to valued that and that offering mean was It I does a I'm know it, are our undervalued north prior secondary the today? where from is here where Overvalued? valuation I've We've one still to come that are. $X.XX of out. that Reasonably from. trying trading company

and I'm just I've more aggressive than I out crunch So that even figure have if trying to to been. be

Ken Berlin

Right.

kick may Martin, So my look. but question, lawyers and me, good

the we've to got yes, announced I look is, the in come down think exciting And portfolio. at price a we back the stock way since it has pretty financing September.

down for most biotechs? we bad have. month If October, biotechs, gone most all for a was it so, than at We have you more look biotechs,

and by I/II the it I Phase the cheap a data readouts Phase the with program it's point company lung around program guess and prostate pretty the HOT in today Phase I NEO would with Phase saying, summarize a asset, soon-to-be III entry I corner. the So program I in

can't job entry So execute. it's My I good that's the people point. a to stock, advocate but not is that job. my to pretty buy think we

think I success to there's well yes, from improvement So company valuation, forward. the catalysts I today that for plan and opportunity with think going position for readouts are coming our the potentially outlined data the the that we've

Martin Saltzman

organization it we you what's to action done curious: you if this debt if at are, wanted that know beyond Massive, use like you money fair the the to that's financing, more see would if you have financing happened and to for and entertained answer. get – even need financing? entertained different a Because a just just I a call you're I’m Have dilutive a with you equity do seems versus entertaining XXXX. that – here all?

Ken Berlin

question. that's a Martin, So good

willing avenues these to for different we programs, we're in they're and worth think funding. think I funding explore

of said, we have we months XX I over imminently. As so now, cash need to right anything do don't

dilutive bring we're to capital, door. raising approaches means the exploring least include could capital the debt, So to in other which

obviously we're would all a all love avenues, do happen. least and be nondilutive certainly current that be we through given BD effort, guaranteed we'd approach think the but financing approach, again, exploring But some dilutive agree, right I the valuation. to can't to best now

Martin Saltzman

your I looking Also, I your to going doesn't presentation events. ASHE. at, on these calendar, was SITC at of and you're like attending seem the it be I plan present website, presenting? other on say, was some or conferences and noticed events Do let's or you

Ken Berlin

be we hopefully soon. to this going talking be share like of need at that later that's important question. up different also be So next be Yes, And is other we'll we're The updating. conference as neoantigen month Martin, website conferences the at and conferences and coming Boston. we're looking the at making other we'll in SITC, can progress programs. And about more good we're on well in we'll at taking AACR where our year. And ASCO

yes, very can next are month understand conferences going why we you, people be and at So at of continue where we up conferences, story even investor so soon and as SITC, overall. can we're presenting among about tell coming observant so other but we and excited different the as I'll to will be

Operator

Please There or remarks. time. closing any your this with presentation no proceed at questions are further

Ken Berlin

questions. to Again, participating on you thank for for call and your today's like all I'd

Our Advaxis today. associates working are partners the with diligently clinical in execute our development out laid plan we collaboration to

updates Thanks provide warranted. on continued will progress We appreciate interest your again. in We as Advaxis. our

Operator

Ladies thank call that you for and that ask concludes conference gentlemen, today. please your lines. your participation We and you for disconnect your

Advaxis (ADXS) 2 Nov 182018 Q3 Earnings call transcript